New Ebola treatment trial brings hope to communities in eastern Congo

People living in eastern Democratic Republic of Congo are looking toward a new medical study with hope as researchers begin testing experimental treatments to fight the country's latest Ebola outbreak.

People living in eastern Democratic Republic of Congo are looking toward a new medical study with hope as researchers begin testing experimental treatments to fight the country’s latest Ebola outbreak. The trial has started in Bunia, one of the areas most severely affected by the virus, where doctors continue to battle a growing number of infections and deaths.

The research officially began in early July at the Ebola treatment centre inside Bunia’s Evangelical Medical Centre. There was no formal ceremony to mark the occasion as medical teams remained focused on caring for patients arriving throughout the day. Ambulances continued bringing in new cases while healthcare workers wearing full protective equipment worked inside isolation units treating those infected with the deadly virus.

The current outbreak is caused by the Bundibugyo strain of Ebola, which is less common than other forms of the disease. Unlike some previous Ebola outbreaks, there are currently no approved vaccines or specific treatments available for this strain. According to the World Health Organization, more than 1,400 people have been infected during the outbreak and at least 438 have lost their lives.

The new study will examine whether the antiviral drug remdesivir, the experimental antibody treatment MBP134 or a combination of both can improve survival among Ebola patients. Researchers will monitor each participant for 28 days after treatment begins to determine how effective the medicines are in fighting the infection.

The trial is being supported by the World Health Organization and involves several international partners, including Congo’s National Institute for Biomedical Research, the University of Oxford, the Institute of Tropical Medicine in Antwerp and other global health organisations. Experts believe the research could play an important role in developing effective treatment options for the Bundibugyo strain.

For now, the study is limited to patients receiving care at specialised Ebola treatment centres. Health officials say a second stage will later include healthcare workers, close contacts of infected patients and other people considered to be at high risk of catching the virus. Researchers expect the study to continue for between three and six months, depending on how the outbreak develops.

Many residents of Bunia see the trial as a much needed source of hope after weeks of fear and uncertainty. Local resident Audrey Tengetenge said the research feels like a chance to finally bring the outbreak under control and reduce the suffering experienced by families across the region.

Ebola survivor Gladys Munguro also welcomed the start of the study. After recently recovering from the disease, she recalled seeing several fellow patients die while she was receiving treatment. She believes the new medicines could improve survival rates and has expressed her willingness to volunteer when the next phase of the research opens to people at high risk of infection.

Despite the optimism, health officials continue to face serious challenges. Some members of the community remain suspicious of medical research and are reluctant to take part in clinical trials. Others have questioned whether the treatments are safe enough to be tested on local residents. At the same time, overcrowded treatment centres, delayed medical care and ongoing violence in parts of eastern Congo have made it difficult for healthcare workers to reach affected communities.

Officials say nearly three quarters of Ebola related deaths during the current outbreak have occurred outside health facilities, highlighting the urgent need for faster diagnosis and treatment. Authorities hope to expand the trial to additional locations once security conditions improve, giving more patients access to the experimental treatments that could help slow the spread of the disease.